

Sasker Fm Grootjans

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6407960/sasker-fm-grootjans-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11 papers	1,509 citations	10 h-index	12 g-index
12 ext. papers	1,808 ext. citations	8.6 avg, IF	4.48 L-index

#	Paper	IF	Citations
11	USP8 suppresses death receptor-mediated apoptosis by enhancing FLIP stability. <i>Oncogene</i> , 2017 , 36, 458-470	9.2	33
10	Initiation and execution mechanisms of necroptosis: an overview. <i>Cell Death and Differentiation</i> , 2017 , 24, 1184-1195	12.7	235
9	A real-time fluorometric method for the simultaneous detection of cell death type and rate. <i>Nature Protocols</i> , 2016 , 11, 1444-54	18.8	31
8	Generation of a new Gateway-compatible inducible lentiviral vector platform allowing easy derivation of co-transduced cells. <i>BioTechniques</i> , 2016 , 60, 252-9	2.5	8
7	Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors. <i>Blood</i> , 2016 , 127, 139-48	2.2	123
6	Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. <i>Cell Death and Disease</i> , 2014 , 5, e1004	9.8	148
5	Methods to Study and Distinguish Necroptosis 2014 , 335-361		2
4	RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. <i>Cell Death and Differentiation</i> , 2013 , 20, 1381-92	12.7	209
3	Determination of apoptotic and necrotic cell death in vitro and in vivo. <i>Methods</i> , 2013 , 61, 117-29	4.6	163
2	Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide. <i>Anti-Cancer Drugs</i> , 2012 , 23, 883-96	2.4	144
1	Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. <i>Cell Death and Disease</i> , 2012 , 3, e437	9.8	290